- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00733174
Rosiglitazone Therapy In The Prevention Of Coronary Artery Disease In Patients With Impaired Glucose Tolerance
August 11, 2008 updated by: Denver Research Institute
Subjects with impaired glucose tolerance will be randomized to either rosiglitazone or placebo for a 18 month period.
The study will look at baseline, 12 month and 18 month data for exercise tolerance, coronary artery calcification and diabetes indicators.
Study Overview
Status
Unknown
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Anticipated)
60
Phase
- Phase 4
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Stacey Mitchell, BSN, RN
- Phone Number: 2059 303-399-8020
- Email: stacey.mitchell@va.gov
Study Locations
-
-
Colorado
-
Denver, Colorado, United States, 80219
- Recruiting
- South Federal Family Practice
-
Contact:
- Stacey Mitchell, BSN, RN
- Phone Number: 2059 303-399-8020
- Email: stacey.mitchell@va.gov
-
Contact:
- Annette Grissett, MA
- Phone Number: 303-934-2202
- Email: annetteg@roydurbin.com
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
25 years to 75 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Subjects must sign the informed consent to participate in the study.
- Male or female adults ages 25-75 years.
- Female subjects must be postmenopausal (i.e., > 6 months without menstrual period), surgically sterile, or using effective barrier contraceptive measures (Intra-Uterine Device (IUD), diaphragm with spermicide or condom with spermicide).
- Women of childbearing potential must use effective barrier contraceptive measures for at least 1 month prior to visit 1, and should continue to use the same contraceptive method during the study and for 30 days after discontinuing study medication.
- Female subjects of childbearing potential must have a negative urine pregnancy test.
- Subjects must have an FPG < 126 mg/dL at Screening 1 AND Screening 2, a C-peptide > 2.0 ng/mL and a HbA1c <6.5%.
- Subjects must have a Body Mass Index 25-40 (must be < 300 lbs).
- Subjects must have a 2 hour post-prandial glucose 140-199 mg/dL at Screening 1 AND Screening 2. If the 2 hour post-prandial glucose result is 130-139 mg/dL at Screening 2, subjects will be allowed to repeat the OGTT.
Exclusion Criteria:
- Women who are lactating, pregnant, or planning to become pregnant during the study will be excluded.
- Women using hormone contraception or on hormone replacement therapy will be excluded.
- Subjects with any clinically significant abnormality identified on the Screening physical examination, laboratory tests, or electrocardiogram which, in the judgment of the Investigator, would preclude safe completion of the study will also be excluded.
- Use of any other investigational agents or participation in any other investigational studies during the study period will not be allowed.
- Patients will also be excluded if there is a presence of clinically significant hepatic disease or patient with LFT levels > 2 times the upper limit of normal laboratory range
- Subjects with a documented history of significant hypersensitivity (e.g., difficulty swallowing, difficulty breathing, tachycardia or skin reaction) to thiazolidinediones
- Subjects with any contraindications to rosiglitazone
- Presence of unstable or severe (New York Heart Association-NYHA class 3 or 4) angina, including angina requiring continual nitrate treatment for symptomatic relief, or coronary insufficiency
- Subjects with HYHA class 3 or 4 of congestive heart failure requiring drug therapy; systolic blood pressure > 160 mmHg or diastolic blood pressure > 100 mmHg
- History of cancer (except non-melanomatous skin carcinoma)
- Active alcohol or drug abuse within the last 6 months
- Subjects with chronic diseases requiring periodic or intermittent treatment with oral or intravenous corticosteroids
- Subjects who are unable to understand dosing directions or swallow study medications
- Subjects who are currently smoking
- Subjects unable to adhere to protocol requirements.
- Persons with angina or any other cardiac or pulmonary symptoms that would potentially limit exercise performance will be excluded.
- Persons taking prescription or over-the-counter weight loss medications or persons on a weight loss program with ongoing weight loss, or starting an intensive exercise program within 30 days of screening will also be excluded.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: 2
Placebo
|
|
Experimental: 1
Rosiglitazone
|
tablet
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Effect of rosiglitazone vs. placebo on exercise tolerance
Time Frame: 18 months
|
18 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
March 1, 2004
Primary Completion (Anticipated)
January 1, 2009
Study Registration Dates
First Submitted
August 8, 2008
First Submitted That Met QC Criteria
August 11, 2008
First Posted (Estimate)
August 12, 2008
Study Record Updates
Last Update Posted (Estimate)
August 12, 2008
Last Update Submitted That Met QC Criteria
August 11, 2008
Last Verified
August 1, 2008
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Heart Diseases
- Cardiovascular Diseases
- Vascular Diseases
- Glucose Metabolism Disorders
- Metabolic Diseases
- Arteriosclerosis
- Arterial Occlusive Diseases
- Hyperglycemia
- Coronary Artery Disease
- Myocardial Ischemia
- Coronary Disease
- Glucose Intolerance
- Hypoglycemic Agents
- Physiological Effects of Drugs
- Rosiglitazone
Other Study ID Numbers
- 101797
- COMIRB NO: 03-755
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Impaired Glucose Tolerance
-
Psychiatric Centre RigshospitaletUniversity of Cambridge; University Hospital, Gentofte, CopenhagenUnknownImpaired Glucose Tolerance Associated With DrugsDenmark
-
Columbia UniversityCompletedBody Weight | Impaired Glucose Tolerance in ObeseUnited States
-
Maastricht University Medical CenterCompletedObesity | Insulin Resistance | Impaired Glucose Tolerance in ObeseNetherlands
-
The University of Texas Health Science Center at...Amylin Pharmaceuticals, LLC.CompletedDiabetes | Impaired Glucose Tolerance (IGT)United States
-
Wroclaw Medical UniversityCompletedPreDiabetes | Impaired Glucose Tolerance (IGT) | Impaired Fasting Glucose (IFG)Poland
-
Yale UniversityNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)CompletedT2D | IGT - Impaired Glucose ToleranceUnited States
-
The University of Texas Health Science Center at...National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); A... and other collaboratorsRecruitingDiabetes Mellitus, Type 2 | Impaired Glucose Tolerance (IGT) | Impaired Fasting Glucose (IFG)United States
-
University of Oslo School of PharmacyCompletedRenal Transplant Recipients | Posttransplant Diabetes Mellitus | Posttransplant Impaired Glucose ToleranceNorway
-
University of OsloCompleted
Clinical Trials on Placebo
-
SamA Pharmaceutical Co., LtdUnknownAcute Bronchitis | Acute Upper Respiratory Tract InfectionKorea, Republic of
-
National Institute on Drug Abuse (NIDA)CompletedCannabis UseUnited States
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyCompletedMale Subjects With Type II Diabetes (T2DM)Germany
-
Heptares Therapeutics LimitedCompletedPharmacokinetics | Safety IssuesUnited Kingdom
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited Kingdom, Netherlands
-
ItalfarmacoCompletedBecker Muscular DystrophyNetherlands, Italy
-
Shijiazhuang Yiling Pharmaceutical Co. LtdXuanwu Hospital, BeijingCompleted
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States
-
West Penn Allegheny Health SystemCompletedAsthma | Allergic RhinitisUnited States